Today the ALS Therapy Development Institute announced that its Board of Directors elected Andrew Niblock of Greenwich, Connecticut, as its newest member. Niblock becomes the 20th member of the board of ALS TDI, as well as the third person living with ALS currently serving as a board member of the world’s largest independent ALS research center.
“Andrew brings to the board vast experiences as an educator and a motivational leader. He understands the battle people with ALS face today all too personally. The board, our scientists and staff welcome Andrew and look forward to working closely with him to advance our mission to discover and develop effective treatments for ALS,” says Steve Perrin, Ph.D., CEO & CSO of ALS TDI.
Andrew Niblock is the Director of Schoolwide Initiatives and the former Head of Lower School at the Greenwich Country Day School in Greenwich. Prior to his current position he was the Director of Lower School at Hamden Hall Country Day School and spent eleven years as a teacher, coach and administrator at Isidore Newman School in New Orleans. In July 2016 Andrew was diagnosed with ALS. In the time since, Andrew and his family have become more hopeful, not less. Andrew's life's work is education, and this is the lens through which he views ALS.
Regarding his election to the board, Mr. Niblock says, “There has never been a more exciting time in ALS science. The creativity that comes with looking at problems from different angles, collaboratively, and with unprecedented advances in technology, gives justified cause for hope. The avalanche of ideas in the scientific world of this fight calls for commensurate creativity in the world of support.”
View a full list of board members of the ALS Therapy Development Institute online here: https://www.als.net/about-als-tdi/als-tdi-board-of-directors/
About the ALS Therapy Development Institute (www.als.net)
The ALS Therapy Development Institute (ALS TDI) and its scientists actively discover and develop treatments for ALS. It is the world’s first and largest nonprofit biotech focused 100 percent on ALS research. Led by people with ALS and drug development experts, ALS TDI understands the urgent need to slow and stop this disease.
Based in Cambridge, MA, ALS TDI has over 30 full-time, industry trained, drug development experts on staff. ALS TDI is internationally recognized as a leader in optimizing preclinical models of neurodegeneration for clinical translation, and partners with pharmaceutical and biotech companies around the world.
Rated a CharityNavigator.com four-star charity, ALS TDI spends 87% of each dollar raised on research to find an effective treatment and cure.